Anika Therapeutics Inc(ANIK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.27 | Insider Own | 6.28% | Shs Outstand | 13.4M | Perf Week | 4.61% |
| Market Cap | 0.29B | Forward P/E | 22.68 | EPS next Y | -9.52% | Insider Trans | 2.34% | Shs Float | 12.5M | Perf Month | 8.05% |
| Enterprise Value | 0.28B | PEG | 0.19 | EPS next Q | 0.42 | Inst Own | 91.69% | Short Float | 2.92% | Perf Quarter | 19.26% |
| Income | -0.00B | P/S | 2.39 | EPS this Y | 854.55% | Inst Trans | -0.96% | Short Ratio | 3.35 | Perf Half Y | 73.93% |
| Sales | 0.12B | P/B | 2.1 | EPS next 5Y | 118.66% | ROA | -1.68% | Short Interest | 0.37M | Perf YTD | 124.25% |
| Book/sh | 10.26 | P/C | 7.51 | EPS past 3/5Y | 9.4% 14.76% | ROE | -2.19% | 52W High | -5.81% ($22.88) | Perf Year | 121.25% |
| Cash/sh | 2.87 | P/FCF | 515.01 | Sales past 3/5Y | -10.28% -2.86% | ROIC | -2.36% | 52W Low | 139.18% ($9.01) | Perf 3Y | 16.3% |
| Dividend Est. | - | EV/EBITDA | 539.7 | EPS Y/Y TTM | 93.57% | Gross Margin | 62.16% | Volatility(W/M) | 3.53% 3.82% | Perf 5Y | -49.64% |
| Dividend TTM | - | EV/Sales | 2.28 | Sales Y/Y TTM | -2.5% | Oper. Margin | -4.24% | ATR (14) | 0.73 | Perf 10Y | -49.88% |
| Dividend Ex-Date | - | Quick Ratio | 3.19 | EPS Q/Q | 187.26% | Profit Margin | -3.14% | RSI (14) | 62.04 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.48 | Sales Q/Q | 15.56% | SMA20 | 6.29% ($20.27) | Beta | 0.23 | Target Price | $23 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/11/6 | SMA50 | 4.31% ($20.66) | Rel Volume | 0.89 | Prev Close | $21.35 |
| Employees | 235 | LT Debt/Eq | 0.17 | EPS/Sales Surpr. | 1300% 11.62% | SMA200 | 35.06% ($15.96) | Avg Volume(3M) | 0.11M | Price | $21.55 |
| IPO | 1993/5/3 | Option/Short | Yes/Yes | Trades | 1666 | Volume | 97,796 | Change | 0.94% |
🦴 Anika Therapeutics (ANIK) is a U.S. medical company that develops, manufactures, and sells osteoarthritis pain management and orthopedic regenerative solutions based on its proprietary hyaluronic acid (HA) technology. The company operates with two main pillars — joint injection products such as Orthovisc and Monovisc, and a regenerative medicine portfolio — positioning its core HA technology as a key competitive differentiator in the specialty healthcare space.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
Next earnings report: November 6
8 days to go.
ANIK has a sound balance sheet but weak earning power
Of every $100 in sales, $4.24 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +854.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $239. Peers typically go for $212.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -49.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 91.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #44 of 83 in the industry
Based on market cap of $288M.
ANIK#44 Anika Therapeutics Inc $288M PER - 
CGC#45 Canopy Growth Corp $282M PER - 
BIOA#46 BioAge Labs Inc $273M PER - 
ACB#47 Aurora Cannabis Inc $268M PER - 
LFCR#48 Lifecore Biomedical Inc $247M PER - 
FAQ
What kind of company is ANIK?
ANIK belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ANIK?
The market cap of ANIK is approximately $288M, ranking 3,696 within its sector.
What is the 52-week high and low for ANIK?
ANIK has recorded a 52-week high of $22.88 and a low of $9.01.
